Fermentalg Reports 17% Revenue Growth in 2025, Eyes Further Expansion in 2026

Fermentalg, a leading company in BioSolutions from aquatic microorganisms, has announced a record revenue of €13.4 million for 2025, marking a 17% increase from the previous year. This growth surpasses their earlier forecast of €13 million despite challenges in the macroeconomic environment.

Key advancements include the launch of new products such as the EPA/DHA ΩRIGINS™ range and Galdieria Blue™, complemented by significant investments in production capacity. Strategic investor Huvepharma has backed these initiatives, supporting Fermentalg’s target of achieving €20 million in revenue by 2026 and up to €50 million long-term.

The company is also poised for initial market penetration in new segments like infant nutrition and functional beverages, with efforts to achieve operational break-even bolstered by forthcoming financial support from Huvepharma.